Clinical Scorecard: Transmission Patterns, Infectiousness, and Viral Longevity in Bundibugyo Virus Disease

At a Glance

Key Highlights

• Previous BDBV outbreaks had reported case fatality rates of approximately 30% to 50%; as of June 6, 2026, the ongoing outbreak in the Democratic Republic of the Congo had a reported rate of 17.7%, although this estimate required cautious interpretation.

• Transmission occurs primarily through direct contact with the blood or body fluids of symptomatic or deceased individuals.

• No authorized vaccine or specific antiviral treatment for BDBV is currently available.

• Presymptomatic transmission has not been documented in humans, although animal-model evidence supports its biological plausibility.

• No BDBV-specific evidence is available on post-recovery viral persistence or transmission from survivors; current recommendations rely largely on evidence involving other orthoebolaviruses.

Guideline-Based Recommendations

Diagnosis

• The article does not provide specific recommendations for diagnosing BDBV infection.

• Clinical recovery and laboratory evidence of viral clearance from blood are used to indicate a substantially reduced risk of transmission through usual routes.

Management

• Implement rigorous infection prevention and control measures, including appropriate personal protective equipment in healthcare settings and safe burial practices.

• Promptly isolate symptomatic individuals as part of outbreak-control efforts.

Monitoring & Follow-up

• Use symptom-based surveillance and monitor contacts for symptom development.

• Provide survivors with follow-up, counseling, risk-reduction guidance, and clinical vigilance for late manifestations.

• Because BDBV-specific evidence is unavailable, survivor recommendations are based largely on evidence involving other orthoebolaviruses.

Risks

• Transmission risk is elevated in healthcare settings when adequate personal protective equipment is not used and during direct contact with deceased individuals in burial-related activities.

• Although delayed transmission associated with viral persistence has been documented for other orthoebolaviruses, the corresponding risk for BDBV remains unknown.

Patient & Prescribing Data

No authorized vaccine or specific antiviral treatment is currently available for BDBV. The article does not provide prescribing data or treatment-specific recommendations.

Clinical Best Practices

• Apply rigorous infection prevention and control measures in healthcare settings.

• Promote safe burial practices to reduce exposure to deceased individuals.

• Conduct contact monitoring and promptly isolate individuals who develop symptoms.

• Provide appropriate counseling and follow-up for survivors while recognizing that current guidance is largely extrapolated from other orthoebolaviruses.

Related Resources & Content

• Wamala JF, Lukwago L, Malimbo M, et al. Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007–2008. Emerg Infect Dis. 2010;16(7):1087–1092.

• MacNeil A, Farnon EC, Morgan OW, et al. Filovirus outbreak detection and surveillance: Lessons from Bundibugyo. J Infect Dis. 2011;204(suppl 3):S761–S767.

• Kratz T, Roddy P, Tshomba Oloma A, et al. Ebola virus disease outbreak in Isiro, Democratic Republic of the Congo, 2012: Signs and symptoms, management and outcomes. PLoS One. 2015;10(6):e0129333.

• Lewis CE, Nishiura H, Furuyama W, et al. Experimental infection of Bundibugyo virus in domestic swine leads to viral shedding with evidence of intraspecies transmission. Transbound Emerg Dis. 2024;2024:5350769.

• Clark DV, Kibuuka H, Millard M, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: A retrospective cohort study. Lancet Infect Dis. 2015;15(8):905–912.

• Vetter P, Kaiser L, Schibler M, Ciglenecki I, Bausch DG. Ebola virus shedding and transmission: Review of current evidence. J Infect Dis. 2016;214(suppl 3):S177–S184.

• World Health Organization. Infection prevention and control for Ebola disease and Marburg disease. World Health Organization; 2026.

• World Health Organization. Clinical care for survivors of Ebola virus disease: Interim guidance. World Health Organization; 2016.